JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domínguez, J. M.
Right arrow Articles by Martín, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domínguez, J. M.
Right arrow Articles by Martín, J. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 32, 22423-22427, August 6, 1999


Sordarin Inhibits Fungal Protein Synthesis by Blocking Translocation Differently to Fusidic Acid*

Juan Manuel DomínguezDagger , María G. Gómez-Lorenzo, and J. Julio Martín

From the Research Department, Glaxo Wellcome SA, PTM, C/Severo Ochoa 2, 28760-Tres Cantos, Madrid, Spain

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Sordarin derivatives are selective inhibitors of fungal protein synthesis, which specifically impair elongation factor 2 (EF-2) function. We have studied the effect of sordarin on the ribosome-dependent GTPase activity of EF-2 from Candida albicans in the absence of any other component of the translation system. The effect of sordarin turned out to be dependent both on the ratio of ribosomes to EF-2 and on the nature of the ribosomes. When the amount of EF-2 exceeded that of ribosomes sordarin inhibited the GTPase activity following an inverted bell-shaped dose-response curve, whereas when EF-2 and ribosomes were in equimolar concentrations sordarin yielded a typical sigmoidal dose-dependent inhibition. However, when ricin-treated ribosomes were used, sordarin stimulated the hydrolysis of GTP. These results were compared with those obtained with fusidic acid, showing that both drugs act in a different manner. All these data are consistent with sordarin blocking the elongation cycle at the initial steps of translocation, prior to GTP hydrolysis. In agreement with this conclusion, sordarin prevented the formation of peptidyl-[3H]puromycin on polysomes from Candida albicans.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Sordarin is a natural product originally isolated from broths of Sordaria araneosa (1) (see chemical structure in Fig. 1). The potential of sordarin derivatives as new antifungal drugs of promising therapeutic value has been evidenced recently. Their spectrum includes most fungal pathogens that affect immunocompromised patients, i.e. Candida spp., Cryptococcus neoformans, Pneumocystis carinii, and several endemic American fungi as well as dermatophytes (2). These compounds exert their antifungal activity by selectively inhibiting the elongation step of protein synthesis in the target organisms, but not in higher eukaryotes (3).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Chemical structure of sordarin.

Protein synthesis is an essential process common to all living cells. It is composed of three phases, namely initiation, elongation, and termination. The machinery involved in the process includes mRNA, tRNAs, ribosomes, and several soluble non-ribosomal protein factors. It has been shown recently that elongation factor 2 (EF-2)1 is the only component of the whole system that is able to bind sordarin; although EF-2 itself can bind the drug, high affinity binding requires the presence of ribosomes (4). On the other hand, mutations either in EF-2 or in the ribosomal protein P0 may confer resistance to sordarins in otherwise sensitive strains (5-7). This evidence has led to EF-2 being considered as the primary sordarin-binding protein and the EF-2·ribosome complex as the functional target.

By interacting with the ribosome, EF-2 promotes translocation and catalyzes the hydrolysis of GTP. Translocation is a crucial step in the elongation cycle of protein synthesis. Briefly, it consists of the simultaneous movement of the newly formed peptidyl-tRNA and the recently deacylated tRNA from the ribosomal A site to the P site and from the P site to the E site, respectively, while the ribosome moves ahead one codon on the mRNA. It proceeds through a complicated mechanism where several events take place in a coordinate and precise fashion to maintain translational accuracy. Translocation has been thoroughly studied in prokaryotes, and there are several models attempting to explain the process (see Refs. 8 and 9 for recent reviews), but it is still far from being completely understood. Nevertheless, it is generally accepted that the ribosome oscillates between a pre- and a posttranslocational state, which refers to two small scale, but significantly different, conformational arrangements within the particle. Both states are separated by a high activation energy barrier of 90 kJ/mol, which is reduced by EF-2 in eukaryotes or EF-G in prokaryotes in the direction from PRE to POST (10, 11). The role of GTP hydrolysis in this scenario is not clearly defined. For many years, it was believed that GTP acted as a modulator of the affinity of the elongation factor for the ribosome, as described for G-proteins (12). Accordingly, the EF-2·GTP complex would have high affinity for the PRE ribosome, whereas the EF-2·GDP complex would have low affinity for the POST ribosome. Translocation would thus precede GTP hydrolysis, and the resulting GDP molecule would trigger the release of EF-2 from the ribosome (13). However, it has been postulated recently that GTP hydrolysis occurs before translocation, providing the energy needed for the process (14). Consequently, EF-2 would behave as a mechanical protein more than as a G-protein. Nevertheless, this interpretation is still a matter of debate and has not yet been fully accepted (15, 16).

In the present paper we study the effect of sordarin on GTP hydrolysis catalyzed by EF-2 and ribosomes from the pathogenic yeast Candida albicans, in the absence of any other elements of the protein synthesis machinery (i.e. the so-called "uncoupled GTPase"). The results obtained have allowed us to propose a model that may clarify the mode of action of sordarin and validate this family of compounds, not only as therapeutic agents, but also as useful tools for studying the molecular mechanisms underlying protein synthesis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Elongation factor 2, salt-washed ribosomes, and polysomes were isolated from C. albicans 2005E as described previously (4). EF-2 concentration was determined spectrophotometrically using E280 = 67310 M-1·cm-1 as deduced from its amino acid sequence. Ribosome concentration was also calculated spectrophotometrically assuming one A260 unit corresponds to 18 pmol of ribosomes (17). Sordarin was provided by the Bioprocessing Unit at Glaxo Wellcome R & D (Stevenage, United Kingdom). [gamma -32P]GTP (370 MBq/ml, >185 MBq/nmol) was from Amersham Pharmacia Biotech (Uppsala, Sweden). [8-3H]Puromycin (18.5 MBq/ml, 370 MBq/µmol) was from Moravek Biochemicals (Brea, CA). All other chemicals were from Sigma.

GTPase Activity-- EF-2 and ribosome-dependent GTPase activity was determined in 25-µl reaction mixtures containing 10 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl2, 10 mM DL-dithiothreitol, 500 µM [gamma -32P]GTP (3.5 kBq), 0.5 µM ribosomes, 0.5 µM or 2 µM EF-2 and the corresponding amount of compound tested. Samples were preincubated at room temperature for 15 min with the corresponding drug in the absence of GTP; GTP was added, and mixtures were incubated at 37 °C during 30 min. The released [32P]phosphate was extracted as phosphomolybdate with a cyclohexane:isobutanol, 1:1 (v/v) mixture and the radioactivity measured. Blanks corresponding to spontaneous GTP hydrolysis (in the absence of EF-2 and ribosomes) were subtracted from each determination provided their values never exceeded 5% of the overall. Likewise, GTP hydrolysis due to EF-2 alone and to ribosomes alone were measured and discounted for each sample. For ricin treatment, ribosomes were preincubated for 15 min at 37 °C in the presence of ricin (molar ratio ricin/ribosomes = 10/1) and then used as explained above.

Puromycin Reaction-- Freshly prepared polysomes from C. albicans were tested for their ability to synthesize peptidyl-[3H]puromycin according to (18). Samples containing 5 A260 units of polysomes were incubated with the corresponding drug for 15 min at 30 °C in the presence of 50 mM Tris-HCl, pH 7.5, 80 mM KCl, 10 mM MgCl2, 100 µM GTP, 500 µM ATP, 25 mM phosphocreatine, 70 µg/ml creatine phosphokinase, 200 µg/ml yeast tRNA, 65 µM each of 20 amino acids, and C. albicans lysate (3) (1 mg protein from the lysate/ml of assay). 0.5 nmol of [3H]puromycin was added to each sample and the incubation extended for 60 min at 30 °C in a final volume of 500 µl. The reaction was stopped by the addition of 500 µl of 10% trichloroacetic acid followed by heating at 90 °C for 15 min. Samples were harvested on GF/C filters (Millipore, Bedford, CA) followed by thorough washing with 5% trichloroacetic acid and 90% ethanol, and their radioactivity was counted. Blanks were prepared by addition of trichloroacetic acid before [3H]puromycin, and their values were subtracted in all cases.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Before starting to study the effect of sordarin on the uncoupled GTPase, optimal conditions to perform the assay were explored. Maximum signal to noise ratios were obtained using a 4:1 molar ratio of EF-2 to ribosomes, which led to a 15-fold increase in GTPase activity with respect to that of EF-2 alone (data not shown). The effect of sordarin concentration was studied under these conditions and compared with that of fusidic acid (Fig. 2). While the latter yielded a clear inhibition curve, sordarin produced an inverted bell-shaped dose-response curve. Sordarin caused some inhibition at intermediate concentrations (0.1 µM), but this effect disappeared either at lower or higher levels of the drug. This peculiar behavior can be interpreted as a combination of two processes. As the effect of sordarin in whole-cell and in cell-free protein synthesis is a single dose-response curve (with higher inhibition at increasing concentrations of drug) (3), this result can be considered as an artificial consequence of the nonphysiological conditions of this in vitro assay, most notably the absence of any other components of the elongation cycle apart from EF-2 and ribosomes. Nevertheless, this result may still be indicative of some event which could give a clue to the mode of action of the drug.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of sordarin and fusidic acid on the uncoupled GTPase activity in systems with excess of EF-2 over ribosomes. The assay was performed as described under "Experimental Procedures" using 2 µM EF-2 and 0.5 µM ribosomes. Results presented here correspond to one representative experiment out of three performed in duplicate. Error bars symbolize the S.D. of the mean. , sordarin; open circle , fusidic acid.

To date, one of the most convincing models that fit the artificial uncoupled GTPase reaction to the physiological events that take place in the translocation process is the one proposed by Nygård and Nilsson (19). This model assumes that both ribosomal conformations (PRE and POST) are able to stimulate the intrinsic GTPase activity of EF-2, but with different efficiencies. In addition, both conformations are able to interact with EF-2·GTP, but with different affinities. Essentially, PRE shows high affinity for the EF-2·GTP complex, but low efficiency in stimulating GTPase, whereas POST shows low affinity for the EF-2·GTP complex, but high efficiency in stimulating GTP hydrolysis. This combination of opposite affinities and efficiencies could explain our results if we assume that the high affinity/low catalysis process (due to PRE) is inhibited by sordarin, while the low affinity/high catalysis process (due to POST) is stimulated by the drug. It should be noted that the ribosome preparation used in this assay is a heterogeneous mixture of PRE and POST ribosomes, but according to previous results, the PRE population outnumbers the POST by 4 to 1 (19-21). Consequently, in the absence of any inhibitor, the EF-2·GTP complex would interact mainly with PRE ribosomes as (i) they are present in excess over POST ribosomes and (ii) they show higher affinity for the complex than POST ribosomes. The presence of sordarin would lead to the formation of a nonproductive PRE·EF-2·GTP·sordarin complex, thus explaining the descending half of the curve. On the other hand, the excess of EF-2 present in the assay medium may undergo interaction with the POST ribosomes; this interaction would be negligible in the absence of sordarin as previously proposed (19), but become significant with increasing concentrations of the drug, overcoming the low affinity between POST and EF-2·GTP and giving rise to the second, ascending half of the curve. To summarize, increasing the amount of sordarin would inhibit the first process and stimulate the second one.

All this reasoning is based on the interpretation that the POST ribosomes are responsible for the recovery of GTPase activity at high sordarin concentrations, based on two assumptions: (a) it can only happen when there is an excess of EF-2 in the system and (b) sordarin stimulates the otherwise rare binding of EF-2·GTP to POST. It is obviously essential to confirm whether the experimental data support these assumptions.

The importance of the excess EF-2 can be easily tested by simply decreasing the amount of the protein. The assay was repeated with equimolar mixtures of EF-2 and ribosomes. Under these conditions, sordarin clearly impaired the uncoupled GTPase reaction as shown in Fig. 3, where in contrast to Fig. 2, a "typical" inhibition curve is obtained. It is worth noting that the IC50 value deduced from Fig. 3 is 0.1 µM, which is in good agreement with the corresponding value inferred from the inhibitory half of the curve in Fig. 2 (0.2 µM).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of sordarin on the uncoupled GTPase activity of equimolar mixtures of EF-2 and ribosomes. The assay was performed as described under "Experimental Procedures" using 0.5 µM EF-2 and 0.5 µM ribosomes. Results presented here correspond to one representative experiment out of three performed in duplicate. Error bars symbolize the S.D. of the mean.

Testing the stimulatory effect of sordarin on the interaction between POST ribosomes and EF-2·GTP is more easily done when a homogeneous population of POST ribosomes is available. This can be achieved by treating the ribosomal preparation with ricin. Ricin is a toxin lectin isolated from the seeds of Ricinus communis. It promotes selective depurination of one base in the larger rRNA molecule (22). This modification destroys the dynamic properties of the ribosome, freezing the particle in a single conformation that has been identified with the POST ribosome (23). Fig. 4 shows the effect of sordarin and fusidic acid on the uncoupled GTPase of equimolar EF-2·ribosomes mixtures, when ribosomes were incubated previously with ricin. The result clearly shows an stimulatory effect of sordarin, whereas fusidic acid inhibited the reaction as in the previous experiment. It is interesting to observe that the maximum stimulatory effect is reached at 1.0 µM sordarin, the same concentration at which maximum recovery of activity was observed in Fig. 2.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of sordarin and fusidic acid on the uncoupled GTPase activity of equimolar mixtures of EF-2 and ricin-treated ribosomes. The assay was performed as described under "Experimental Procedures" using 0.5 µM EF-2 and 0.5 µM ribosomes. Results presented here correspond to one representative experiment out of three performed in duplicate. Error bars symbolize the S.D. of the mean. , sordarin; open circle , fusidic acid.

Results shown in Figs. 3 and 4 are in agreement with the assumptions made above. It can also be clearly seen in Fig. 4 that sordarin is not a direct inhibitor of the GTPase activity. Hence, the inhibition observed in Fig. 3 (and partially in Fig. 2) must be considered more as a consequence than as a primary effect. Previous data on the binding of sordarin to EF-2·ribosome complexes (4) make it unlikely that sordarin prevents the interaction between PRE ribosomes (the majority) and EF-2·GTP. It follows that sordarin may directly impair the transition from PRE to POST, thus blocking the ribosome in the pretranslocational state.

To test this conclusion we studied the effect of sordarin on the so-called puromycin reaction (18, 24) and compared it to that of cycloheximide and fusidic acid. This is a classical tool for exploring the mode of action of protein synthesis inhibitors. It is based on the different accessibility of the ribosomal A site to radiolabeled puromycin depending on whether the ribosome is in PRE (i.e. A site inaccessible to puromycin) or in POST (A site accessible).

Actively translating polysomes were isolated from C. albicans. In the absence of any other drug, [3H]puromycin was incorporated to the nascent peptide chains (Fig. 5). This same result was obtained when polysomes were previously incubated with fusidic acid, as expected (25). However, a significant decrease in the incorporation of [3H]puromycin was observed when polysomes were preincubated with sordarin, a result similar to that obtained with cycloheximide. Anisomycin, a known inhibitor of peptide bond formation (20), also reduced the amount of peptidyl-[3H]puromycin formed. The effect of sordarin was clearly dose-dependent as deduced from Fig. 6, although it was not possible to reach total inhibition of the reaction. This fact is explained by the spontaneous translocation undergone by a fraction of the polysomes during the isolation procedure previous to incubation with the inhibitor. Consequently, the mode of action of sordarin seems to be closer to that of cycloheximide (inhibition of the translocation step (20)) than to that of fusidic acid (inhibition of the turnover of EF-2·GDP from the POST ribosome (26)).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of sordarin and other protein synthesis inhibitors on the synthesis of peptidyl-[3H]puromycin. The assay was performed as described under "Experimental Procedures." Results presented here correspond to one representative experiment out of two performed in duplicate. Error bars symbolize the S.D. of the mean. Ctrl, control; Sord., 2 mM sordarin; Cycl., 20 mM cycloheximide; Fus., 200 mM fusidic acid; Anis., 500 µM anisomycin.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Dose-response curve of sordarin on the puromycin reaction. The assay was performed as described under "Experimental Procedures." Results presented here correspond to one representative experiment out of two performed in duplicate. Error bars symbolize the S.D. of the mean.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The unexpected shape of the dose-response curve obtained when studying the effect of sordarin on the uncoupled GTPase reaction catalyzed by C. albicans EF-2 may give a clue to the precise mode of action of the drug. The curve has been interpreted on the basis of the two reciprocating conformations of the ribosome and has been considered a consequence of the experimental conditions used in the assay, mainly the large excess of EF-2 over ribosomes and the heterogeneous nature of the ribosomal preparation, which is a mixture of PRE and POST particles. Changing these conditions gives rise to a complete change of the curve shape. From a qualitative point of view, the sordarin curve in Fig. 2 can be considered a combination of the corresponding curves in Figs. 3 and 4, in agreement with the interpretation that the former result is due to a combination of two processes. A full cycle describing the molecular events taking place in vitro in the uncoupled GTPase assay is depicted in Fig. 7, an adaptation of the model described by Nygård and Nilsson (19). According to our results, sordarin is not a direct inhibitor of the GTPase activity, since the drug is able to stimulate GTP hydrolysis under certain conditions. Inhibition of this activity, when observed, seems to be a consequence of blocking the elongation cycle at a point prior to GTP hydrolysis, in agreement with the inhibition of the puromycin reaction achieved with sordarin. There are two ways to inhibit the cycle upstream of GTP hydrolysis: by preventing the interaction between PRE and EF-2·GTP or by blocking the transition from PRE·EF-2·GTP to POST·EF-2·GTP. The first possibility is considered unlikely in the light of previous results showing high affinity binding between sordarin and the ribosome·EF-2 complex. The evidence points therefore to the transition from PRE·EF-2·GTP to POST·EF-2·GTP as the protein synthesis step inhibited by sordarin.

In the previous paragraphs we have interpreted our results according to the classical model of translocation suggested by Nygård and Nilsson (19) 10 years ago. Presently more detailed models have been proposed. All of them are based on experimental data obtained with bacteria systems. However there are no apparent reasons not to apply them to eukaryotic systems. The first one is the "hybrid states" model proposed by Moazed and Noller (27), which has evolved into the "elaborated hybrid states" model (8). The latter incorporates the hypothesis formulated by Rodnina et al. (14, 28) that places GTP hydrolysis before translocation and considers GTP the source of energy that allows the mechanical movement of tRNAs and mRNA. The tRNAs move in alternate fashion with respect to ribosomal subunits, thus yielding the designated hybrid states: the acceptor arms of the tRNAs are in the E or P sites of the large ribosomal subunit, while the anticodon arms remain in the P or A sites of the small subunit, respectively. One of the main implications of this model is that the structural rearrangements that take place in the ribosome are subtle local changes rather than gross conformational changes. The model is composed of several intermediate states that are generated in the following sequence: 1) generation of a puromycin-unreactive hybrid state on the pretranslocated ribosome immediately after peptide bond formation, 2) binding of EF-2·GTP, 3) transition to a puromycin-reactive hybrid state, 4) GTP hydrolysis, 5) translocation of the anticodon arms, and 6) release of EF-2·GDP. This sequence of events is compatible with the proposed scheme in Fig. 7. Step 3 may be the one that shifts the PRE conformation of the ribosome into the POST. The subsequent events may exclusively affect tRNAs, mRNA and EF-2·GTP. Accordingly, step 3 would be the one targeted by sordarin.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Proposed scheme for the uncoupled GTPase cycle and sordarin mode of action. The illustration is derived from the model proposed in Ref. 19. Dotted line, rare process due to low catalytic efficiency; dashed line, process negligible under physiological conditions due to low affinity binding; this latter process can be stimulated in vitro either by a large excess of EF-2 or by high sordarin concentrations or both.

The alternative model is the so-called alpha-epsilon model, proposed by Nierhaus and co-workers (29). This model suggests the existence of a movable ribosomal domain (called "alpha -epsilon "), which shifts from the A and P sites to the P and E sites during translocation, carrying with it the tRNAs. The precise role of EF-2 and GTP hydrolysis is not clearly assigned, but by analogy to the previous model, it seems reasonable to propose that the ultimate effect of sordarin may be blocking the movement of the domain.

Recently, Justice et al. (5) have suggested that sordarins stabilize the POST·EF-2·GDP complex in a manner identical to fusidic acid. This conclusion was based on the observation that sordarin hampered the exchange between unlabeled GTP and [3H]GTP previously bound to EF-2 and ribosomes from S. cerevisiae, the ribosomes being in 7-fold excess over the factor. Our results, however, show a completely dissimilar behavior between sordarin and fusidic acid. The result reported by Justice et al. (5) may be explained by the experimental conditions used. A 7-fold excess of ribosomes over EF-2 would lead to most EF-2 molecules being bound by the high affinity PRE ribosomes, which would be locked into a nonproductive PRE·EF-2·GTP complex by sordarins, according to the model in Fig. 7.

Sordarins have proved to be a family of drugs of potential medical and scientific value. Their therapeutic efficacy, their unpaired specificity, and their novel mode of action in the field of antifungals justify their interest. However, the molecular details that account for sordarin activity still remain elusive as the precise events of translocation do. More studies orientated to elucidate the former will also be useful to understand the latter.

    ACKNOWLEDGEMENTS

We thank J. F. Garcia-Bustos for his scientific contribution and discussion of the results, J. P. Garcia-Ballesta for critical reading of the manuscript, and V. A. Kelly for kind linguistic revision.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 34-91-8070301; Fax: 34-91-8070595; E-mail: jmd18916@GlaxoWellcome.co.uk.

    ABBREVIATIONS

The abbreviations used are: EF-2, elongation factor 2; EF-G, elongation factor G; PRE, pretranslocated ribosome; POST, posttranslocated ribosome.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hauser, D., and Sigg, H. P. (1971) Helv. Chim. Acta 54, 1178-1190[CrossRef][Medline] [Order article via Infotrieve]
2. Herreros, E., Martinez, C. M., Almela, M. J., Marriott, M. S., Gomez de las Heras, F., and Gargallo-Viola, D. (1998) Antimicrob. Agents Chemother. 42, 2863-2869[Abstract/Free Full Text]
3. Domínguez, J. M., Kelly, V. A., Kinsman, O. S., Marriott, M. S., Gomez de las Heras, F., and Martin, J. J. (1998) Antimicrob. Agents Chemother. 42, 2274-2278[Abstract/Free Full Text]
4. Domínguez, J. M., and Martin, J. J. (1998) Antimicrob. Agents Chemother. 42, 2279-2283[Abstract/Free Full Text]
5. Justice, M. C., Hsu, M. J., Tse, B., Ku, T., Balkovec, J., Schmatz, D., and Nielsen, J. (1998) J. Biol. Chem. 273, 3148-3151[Abstract/Free Full Text]
6. Capa, L., Mendoza, A., Lavandera, J. L., Gomez de las Heras, F., and Garcia-Bustos, J. F. (1998) Antimicrob. Agents Chemother. 42, 2694-2699[Abstract/Free Full Text]
7. Gómez-Lorenzo, M. G., and Garcia-Bustos, J. F. (1998) J. Biol. Chem. 273, 25041-25044[Abstract/Free Full Text]
8. Wilson, K. S., and Noller, H. F. (1998) Cell 92, 337-349[CrossRef][Medline] [Order article via Infotrieve]
9. Nierhaus, K. H., Stuhrmann, H. B., and Svergun, D. (1998) Prog. Nucleic Acid Res. Mol. Biol. 59, 177-204[Medline] [Order article via Infotrieve]
10. Nierhaus, K. H. (1996) Nature 379, 491-492[CrossRef][Medline] [Order article via Infotrieve]
11. Wilson, K. S., and Noller, H. F. (1998) Cell 92, 131-139[CrossRef][Medline] [Order article via Infotrieve]
12. Liljas, A., Aevarsson, A., Al-Karadaghi, S., Garber, M., Zheltonosova, J., and Brazhnikov, E. (1995) Biochem. Cell Biol. 73, 1209-1216[Medline] [Order article via Infotrieve]
13. Nygård, O., and Nilsson, L. (1990) Eur. J. Biochem. 191, 1-17[Medline] [Order article via Infotrieve]
14. Rodnina, M. V., Savelsbergh, A., Katunin, V. I., and Wintermeyer, W. (1997) Nature 385, 37-41[CrossRef][Medline] [Order article via Infotrieve]
15. Czworkowski, J., and Moore, P. B. (1997) Biochemistry 36, 10327-10334[CrossRef][Medline] [Order article via Infotrieve]
16. Spahn, C. M. T., and Nierhaus, K. H. (1998) Biol. Chem. 379, 753-772[Medline] [Order article via Infotrieve]
17. Spedding, G. (1990) in Ribosomes and Protein Synthesis: A Practical Approach (Spedding, G., ed) , pp. 1-29, IRL Press, Oxford
18. Modolell, J., and Vazquez, D. (1977) Eur. J. Biochem. 81, 491-497[Medline] [Order article via Infotrieve]
19. Nygård, O., and Nilsson, L. (1989) Eur. J. Biochem. 179, 603-608[Medline] [Order article via Infotrieve]
20. Barbacid, M., Fresno, M., and Vazquez, D. (1975) J. Antibiot. (Tokyo) 28, 453-462[Medline] [Order article via Infotrieve]
21. Baliga, B. S., Cohen, S. A., and Munro, H. N. (1970) FEBS Lett. 8, 249-252[CrossRef][Medline] [Order article via Infotrieve]
22. Endo, Y., and Tsurugi, K. (1987) J. Biol. Chem. 262, 8128-8130[Abstract/Free Full Text]
23. Holmberg, L., and Nygård, O. (1996) J. Mol. Biol. 259, 81-94[CrossRef][Medline] [Order article via Infotrieve]
24. Traut, R. R., and Monro, R. E. (1964) J. Mol. Biol. 10, 63-72[Medline] [Order article via Infotrieve]
25. Celma, M. L., Vazquez, D., and Modolell, J. (1972) Biochem. Biophys. Res. Commun. 48, 1240-1246[CrossRef][Medline] [Order article via Infotrieve]
26. Burns, K., Cannon, M., and Cundliffe, E. (1974) FEBS Lett. 40, 219-223[CrossRef][Medline] [Order article via Infotrieve]
27. Moazed, D., and Noller, H. F. (1989) Nature 342, 142-148[CrossRef][Medline] [Order article via Infotrieve]
28. Rodnina, M. V., and Wintermeyer, W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7237-7239[Free Full Text]
29. Dabrowski, M., Spahn, C. M. T., Schäfer, M. A., Patzke, S., and Nierhaus, K. H. (1998) J. Biol. Chem. 273, 32793-32800[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
RNAHome page
A. S. Bommakanti, L. Lindahl, and J. M. Zengel
Mutation from guanine to adenine in 25S rRNA at the position equivalent to E. coli A2058 does not confer erythromycin sensitivity in Sacchromyces cerevisae
RNA, March 1, 2008; 14(3): 460 - 464.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
N. Demeshkina, G. Hirokawa, A. Kaji, and H. Kaji
Novel activity of eukaryotic translocase, eEF2: dissociation of the 80S ribosome into subunits with ATP but not with GTP
Nucleic Acids Res., July 9, 2007; 35(14): 4597 - 4607.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Soe, R. T. Mosley, M. Justice, J. Nielsen-Kahn, M. Shastry, A. R. Merrill, and G. R. Andersen
Sordarin Derivatives Induce a Novel Conformation of the Yeast Ribosome Translocation Factor eEF2
J. Biol. Chem., January 5, 2007; 282(1): 657 - 666.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Santos, M. A. Rodriguez-Gabriel, M. Remacha, and J. P. G. Ballesta
Ribosomal P0 Protein Domain Involved in Selectivity of Antifungal Sordarin Derivatives
Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2930 - 2936.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
E. Herreros, M. J. Almela, S. Lozano, F. Gomez De Las Heras, and D. Gargallo-Viola
Antifungal Activities and Cytotoxicity Studies of Six New Azasordarins
Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3132 - 3139.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
M. Shastry, J. Nielsen, T. Ku, M.-J. Hsu, P. Liberator, J. Anderson, D. Schmatz, and M. C. Justice
Species-specific inhibition of fungal protein synthesis by sordarin: identification of a sordarin-specificity region in eukaryotic elongation factor 2
Microbiology, February 1, 2001; 147(2): 383 - 390.
[Abstract] [Full Text]


Home page
Nucleic Acids ResHome page
C. Briones and J. P. G. Ballesta
Conformational changes induced in the Saccharomyces cerevisiae GTPase-associated rRNA by ribosomal stalk components and a translocation inhibitor
Nucleic Acids Res., November 15, 2000; 28(22): 4497 - 4505.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Dominguez and J. J. Martin
Identification of a Putative Sordarin Binding Site in Candida albicans Elongation Factor 2 by Photoaffinity Labeling
J. Biol. Chem., August 10, 2001; 276(33): 31402 - 31407.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domínguez, J. M.
Right arrow Articles by Martín, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domínguez, J. M.
Right arrow Articles by Martín, J. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.